



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/796,441	03/08/2004	Michael Radomsky	DEPYP003D1C1	1814
22434	7590	02/04/2009		
Weaver Austin Villeneuve & Sampson LLP			EXAMINER	
P.O. BOX 70250			HENRY, MICHAEL C	
OAKLAND, CA 94612-0250				
		ART UNIT	PAPER NUMBER	
		1623		
		MAIL DATE	DELIVERY MODE	
		02/04/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/796,441

Applicant(s)

RADOMSKY, MICHAEL

Examiner

MICHAEL C. HENRY

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 October 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21 and 22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 21 and 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/CI/CDC)
Paper No(s)/Mail Date 01/13/09
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

The following office action is a responsive to the Amendment filed, 10/27/08.

The amendment filed 10/27/08 affects the application, 10/796,441 as follows:

Claim 21 has been amended. The rejections made under 35 U.S.C. 103(a) of the prior office action mailed 06/25/08 are maintained.

1. The responsive to applicants' amendment is contained herein below.

Claims 21-22 are pending in application

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 21-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brekke et al. (WO 9409722).

In claim 21, applicant claims "A method of treating diseased, injured or abnormal bone at a site of desired bone growth comprising the step of applying to said site an injectable composition comprising an effective amount of a mixture of hyaluronic acid, growth factor bFGF and excipients to maintain biological activity of said factor, said composition being sufficient to enhance bone growth rate and magnitude and having a viscosity and biodegradability sufficient to persist at said site for a period of time sufficient to enhance said bone growth rate and magnitude." Claim 22 is drawn to a method according to claim 21 wherein said bFGF is present in a range of about 10^{-6} to 100 mg/ml in said composition.

Brekke et al. disclose a composition for treating bone such as abnormal bone at a site of desired bone growth (e.g., the voids in bone) comprising the step of applying to said site a composition comprising a mixture of hyaluronic acid, growth factor bFGF and excipients, and wherein the said composition can promote (enhance) bone growth (see abstract, page 4, line 20 to page 7, line 11 and especially page 6 the paragraph numbered as 4; also see claims).

The difference between applicant's claimed method and the method taught by Brekke et al. is that Brekke et al. does not exemplify the use of said composition, per se.

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made to have used the method suggested by Brekke et al. to treat abnormal, injured or diseased bone by applying to the site of said abnormal, injured or diseased bone a composition comprising an effective amount of a mixture of hyaluronic acid, a growth factor and excipients and to alter the viscosity of said composition depending on factors such as the severity of the bone condition or disorder and the individual that is being treated.

One having ordinary skill in the art would have been motivated to use the method suggested by Brekke et al. to treat abnormal, injured or diseased bone by applying to the site of said abnormal, injured or diseased bone a composition comprising an effective amount of a mixture of hyaluronic acid, a growth factor and excipients and to alter the viscosity of said composition depending on factors such as the severity of the bone disease and the individual that is being treated. It should also be noted that use of specific concentration of the components (such as bFGF) of said composition also depending on factors such as the severity of the bone condition or disorder and the individual that is being treated.

Response to Arguments

Applicant's arguments with respect to claims 21 and 22 have been considered but are not found convincing.

The applicant argues that for Brekke et al. composition there must be a microstructure composed of the chemotactic ground substance, which can be hyaluronic acid. The hyaluronic acid is used as a solid material, a velour composed of fibrils with intercalated voids of microscopic dimensions. However, Brekke et al. disclose that the hyaluronic acid can be in gel form (see page 20, lines 11-13). Moreover, Brekke et al. composition like applicant's composition (as claimed) comprises the same said ingredients or components (regardless of form or state of components). Also, it should be noted that Brekke et al.'s composition like applicant's composition is also biodegradable.

The applicant argues that Brekke requires the osteoinductive/osteogenic substance which is a growth factor. These requirements dictate the use of a solid composition as shown in Brekke's FIGS. 1-6, and described on page 20, lines 18-26. However, Brekke et al. disclose that their osteoinductive/osteogenic substance or growth factor can be injected in or as a solution (see page 19, last paragraph to page 20, 1st paragraph). Moreover, Brekke et al. composition like applicant's composition (as claimed) comprises the same said ingredients or components (regardless of form or state of components). Also, it should be noted that Brekke et al.'s composition like applicant's composition is also biodegradable.

The applicant argues that the presently claimed method requires the use of an injectable composition. However, Brekke et al. method also requires the use of a composition that is also considered an injectable composition since it can be injected into the site that is being treated. In addition, it is important to note that applicant's method (as claimed) requires the

composition be applied to the site. Thus, Brekke et al. does not teach away from the presently claimed method composition as argued by applicant.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry
January 31, 2008.

/Shaojia Anna Jiang/
Supervisory Patent Examiner
Art Unit 1623